Radiofrequency volume reduction (RFTVR) is a minor procedure directed at reducing the tongue base volume to treat obstructive sleep apnea. Subjective and objective treatment effectiveness was evaluated. STUDY DESIGN AND SETTING: Two separate prospective, matched, nonrandomized, open enrollment treatment groups (RFTVR, n = 73 and nasal continuous positive airway pressure (CPAP, n = 99) were concurrently enrolled in a multicenter study. RESULTS: Fifty-six (76.7%) RFTVR completed PSG with a mean 5.4 ± 1.8 treatments (13,394 ± 5459 joules). Perioperatively, acute pain was mild to moderate; edema, mucosal erosion, paresthesia, tinnitus were infrequent; and speech, swallowing taste, or throat irritation were unchanged. Self-reported outcomes did not differ between RFTVR and CPAP groups. Mean apnea/hypopnea index decreased (40.5 ± 21.5 to 32.8 ± 22.6 events/hr, P < 0.01). Electrolyte solution injected predicted results (r = 0.43, P < 0.001). The most severe complication was abscess (1.1%). CONCLUSION: RFTVR improves apnea/hypopnea index. Improvement may be related to solution injected with treatment. RFTVR and CPAP clinical outcomes improvement were similar. CLINICAL SIGNIFICANCE: In mild obstructive sleep apnea, treatment of symptomatic outcomes with RFTVR may be an alternative to CPAP. (Otolaryngol Head Neck Surg 2001;125:303-11.) Obstructive sleep apnea syndrome (OSAS) affects 2% to 4% of middle-aged adults. 1 Continuous positive airway pressure (CPAP) is the first line treatment and the preferred medical therapy for OSAS. Although it is effective, CPAP requires a high compliance rate and lifelong use. For those patients who are nontolerant or unsuccessful of nasal CPAP, surgical treatment is an alternative. Tracheostomy, which completely bypasses the upper airway, is a historically successful treatment, but is problematic due to morbidity and chronic maintenance issues. It is currently reserved for extreme cases only. Maxillofacial surgery may offer a high success rate but has not yet been widely accepted by physicians or patients. The ideal treatment for OSAS would be a surgical procedure that provides an equivalent outcome to CPAP with minimal morbidity.
Obstructive sleep apnea syndrome (OSAS) affects 2% to 4% of middle-aged adults. 1 Continuous positive airway pressure (CPAP) is the first line treatment and the preferred medical therapy for OSAS. Although it is effective, CPAP requires a high compliance rate and lifelong use. For those patients who are nontolerant or unsuccessful of nasal CPAP, surgical treatment is an alternative. Tracheostomy, which completely bypasses the upper airway, is a historically successful treatment, but is problematic due to morbidity and chronic maintenance issues. It is currently reserved for extreme cases only. Maxillofacial surgery may offer a high success rate but has not yet been widely accepted by physicians or patients. The ideal treatment for OSAS would be a surgical procedure that provides an equivalent outcome to CPAP with minimal morbidity.
The initial surgical treatment for OSAS is often palatal surgery; however, only 25% of patients have strictly palatal obstruction. 2 Airway collapse in patients with OSAS may occur at multiple sites, including the palate or upper pharynx, and the tongue or lower pharynx. It has been shown that untreated tongue base obstruction is a cause of uvulopalatopharyngoplasty (UPPP) failure. 3 To address this, treatments for tongue base obstruction including glossectomy, genioglossal advancement, and hyoid suspensions have been combined with UPPP. All are invasive procedures with corresponding morbidity but with potentially higher rates of success than UPPP alone.
Recently, temperature-controlled radiofrequency tissue volume reduction has been used to reduce tissue volume in the upper airway. A submucosal ablation is formed by electromagnetic energy in the radiofrequency range inducing ionic agitation within tissue. This causes frictional heating, followed by temperature feedback controlled isothermal conductive lesion expansion. 4 Tongue base reduction using temperaturecontrolled radiofrequency has previously been shown to be a safe and effective treatment for sleep-disordered breathing (SDB) in a feasibility study of 18 patients. 5 This pilot study included patients with disorders ranging from upper airway resistance syndrome (UARS) to severe OSAS who continued to have symptomatic SDB despite previous upper airway operative procedures. At a minimum, all had failed UPPP and demonstrated tongue base obstruction. Using this technology in an ambulatory staged surgical procedure, Powell et al 5 were able to reduce tongue volume by a mean of 17%, bringing the mean respiratory disturbance index (RDI) from 39.6 to 17.8, and the SaO 2 nadir from 81.9% to 88.3% for their patient group.
The study presented here is a multicenter clinical trial designed to see if a similarly selected but larger patient population would validate the results obtained by Powell et al. 5 These patients had all undergone unsuccessful surgical procedures, including site-directed approaches to address retroglossal components of obstruction in some cases. This study evaluates a single level, in-office surgical treatment performed under local anesthesia. Clinical treatment outcomes and quality of life data were compared with a nonrandomly concurrently enrolled CPAP user cohort group in order to determine the efficacy of this procedure.
METHODS

Study Design
This study was designed with 2 separate prospective, nonrandomized patient populations with mild to severe obstructive sleep apnea syndrome (apnea/hypopnea index [AHI] > 15 and < 60). The experimental group was treated with temperature-controlled radiofrequency volumetric tissue reduction (RFVTR) of the tongue base. The control group underwent treatment with nasal CPAP. Subjects were recruited through open enrollment and treated in a prospective but nonrandomized fashion. Nine sites were initially selected as surgical treatment centers (4 academic, 5 nonacademic). In addition, 2 nonacademic sleep centers were selected to recruit patients for nasal CPAP treatment. For both groups, initial selection criteria required an initial AHI of greater than 15 but less than 60 events per hour, a body mass index of less than 35 kg/m 2 , age between 18 and 60 years of age, and anesthesia risk group ASA Class I, II, or III. RFVTR patients were required to have a functioning nasal CPAP unit available in the home for use perioperatively. Patients in the RFVTR group were required to have normal palatal and nasal examination as determined by the treating physician or to have previously undergone adequate treatment for any contributing palatal or nasal obstruction. Adequate palatal treatment could have included either UPPP or LAUP. Patients were excluded with a pre-existing swallowing or speech disorder, severe unstable cardiovascular disease, prior upper respiratory tract cancer or radiation therapy of the upper respiratory tract, active upper respiratory infection, bleeding abnormalities or anticoagulation, neurologic disorders, drug or alcohol abuse, or pregnancy. All institutions received institutional review board (IRB) approval of the protocol before patient enrollment, and all patients provided informed consent.
Outcome variables for the RFVTR treatment arm included self-reported subjective clinical measures, objective respiratory measures, and polysomnography. Enrolled RFVTR patients were screened before initiation of treatment with a thorough general and sleep history, and an upper airway physical examination that included fiberoptic nasopharyngoscopy. Tongue base obstruction was subjectively assessed by the investigator. Screening procedures also involved a formal speech evaluation that was performed before the first treatment and 6 weeks or more after the final treatment by a speech pathologist. The Arizona articulation proficiency scale or similar measures were used to assess speech. Patients underwent evaluation via video fluoroscopic pharyngogram before RFVTR treatment and after final treatment. Complete nocturnal polysomnography was used for assessment of sleep and respiratory outcomes. Attempts were made so that all pre-and postpolysomnograms for a given subject were performed by the same sleep center. Measures of sleep included electroencephalogram, electrooculogram, chin and leg muscle electromyograms, electrocardiogram, measures of respiratory effort, measures of nasal oral airflow, thoracic and abdominal efforts, and pulse oximetry. It was encouraged that body position also be measured. Obstructive apneas were defined as a loss of nasal oral airflow for 10 seconds with evidence of continued respiratory effort. Because of the wide variety of sleep laboratories and technicians participating, it was not possible to establish a consistent definition of hypopnea. Hypopneas were defined using the criteria of the subject's sleep lab. During the course of the study, the definition of hypopnea was further confounded by the publication of the American Academy of Sleep Medicine of revised snoring criteria (the Chicago criteria).
Subjective Outcomes
Several standardized subjective self-reported outcomes measures were used to assess treatment effects on quality of life, sleepiness, and snoring. These self-reported measures were obtained before the onset of treatment and at 8 to 12 weeks after completion of treatment, and included the SF36, SNORE 25, Epworth Sleepiness Scale, and FOSQ. These are further outlined below.
The SF36 is a general health status instrument that uses 8 different domains. Scores for each domain are rated from 0 (worse) to 100 (best). Normative data are available for the SF-36.
The SNORE 25 (Symptoms of Nocturnal ObstructionRelated Events) is a 25-question health survey directed at evaluating symptoms of sleep-disordered breathing. Each question may be answered in a stratified 6-point scale ranging from "no problem" to "as bad as it can be." It is composed of 5 subscales with a maximum score of 125 (bad as it can be) to 0 (no problem).
The Epworth Sleepiness Scale (ESS) is a validated, patient-based instrument that rates the patient's tendency to fall asleep in 8 common daily situations. Subjective sleepiness in each of these nonstimulating situations is reported by the In addition to these self-reported outcomes measures, visual analog scale (VAS) scores were recorded by all RFVTR patients for several perioperative acute outcomes. Scores ranged from 0 (best) to 10 (worst). Physicians evaluated treatment complications with a Likert scale with anchors of none, mild, moderate, or severe, to evaluate the extent of each subject's symptoms. Acute outcomes studied in this fashion included edema, blanching, mucosal erosion, paresthesia, referred pain, and tinnitus.
RFVTR Technique
Temperature-controlled radiofrequency volumetric tissue reduction of the tongue base was performed using the Somnoplasty system (Sunnyvale, CA). This system has previously been described by Powell et al. 5 Briefly, radiofrequency is delivered at 460 kHz using a specifically constructed needle electrode and delivery system. Initially, the experimental design was to replicate the methodology of Powell et al. However, each site investigator was given discretion to modify the technique as deemed necessary. The total number of lesions, total joules applied, total volume of local anesthetic or other fluids injected, and medications provided were documented for each treatment session. For most investigators, methods approximated those of Powell, although with experience, a larger number of lesions were placed per treatment session. As with Powell's treatment, locations were centered at the circumvallate papilla within the middle two thirds of the tongue. Treatments were separated by at least 3 to 4 weeks. During the procedure, continuous monitoring of the blood pressure, EKG, and heart rate were performed. To be eligible for enrollment, all subjects had to agree to use nasal CPAP or have tracheotomy perioperatively. Local anesthesia was achieved by direct injection of 0.25% bupivacaine, or 1% to 2% lidocaine with or without epinephrine. One investigator (T.H.) supplemented local anesthesia with an injection of 1.5 to 2 cc of sterile saline solution immediately before insertion of the electrode to increase ionic concentration and theoretically enhance lesion creation. Initially, investigators performed chorda tympani and lingual nerve blocks but this was largely abandoned by the end of the study, as they proved unnecessary. All subjects were admitted for hospital overnight respiratory observation and pulse oxymetry after the first treatment session. All subsequent treatments were performed and patients discharged to home. Complications were reported by investigators and were rated according to the investigators as being mild, moderate, or severe. Adverse events were also classified by the investigators as to their relationship to radiofrequency treatment.
Statistical Analysis
Statistical analysis was performed by Quintiles, Inc (South San Francisco, CA). Statistically significant results were based on a Type 1 error rate of 0.05. Treatment variables were assessed using the Wilcoxon 2 sample test and the Fischer's exact test. Objective treatment outcomes were assessed using a paired Student t test when appropriate or analysis of variance (ANOVA). In order to compare treatment effects across different treatment groups, effect size was used to standardize treatment effects for each outcome measure. 6 The effect size is calculated as follows: effect size = the mean change of the outcome measure ÷ the standard deviation of the initial measure. Effect size of 0 to 0.2 are small, 0.2 to 0.8 moderate, and greater than 0.8 are large. Standard linear regression was used to evaluate the relationship of electrolyte changes to AHI.
RESULTS
Seventy-three surgical patients were enrolled; 56 (76.7%) of them had pre-and posttreatment polysomnography. Ten patients were lost to follow-up or withdrew from the study before completion. Four patients had initial split night polysomnography that precluded inclusion into objective outcomes. Two patients failed to receive posttreatment polysomnography, and one had interval UPPP during the study. Sixty-nine patients (64 male, 5 female) provided pre-and posttreatment subjective outcome data. Demographic information for the group is provided in Table 1 . As a group, subjects were obese, with a mean body mass index (BMI) of 30.6 ± 4.1 kg/m 2 . Patients demonstrated a broad distribution of OSAS severity. Fourteen had mild OSAS (AHI < 20 events per hour), 24 patients had moderate OSAS (AHI 20 to 40 events per hour), and 27 patients had severe OSAS (AHI > 40 events per hour). Sixty-five patients (92.9%) had prior pharyngeal surgery ( Table 2 ). The most common prior procedure was UPPP (n = 57/70, 81.4%).
Patients received a mean of 5.4 ± 1.8 treatments (range, 2 to 11). For all sites and all patients, a total of 355 treatments were performed. The mean number of lesions per treatment session was 3.1 ± 0.90. Average Joules per patient were 13,994 ± 5,459. Mean number of Joules per treatment session was 2,720 ± 960. Posttreatment pain was rated as mild to moderate. On day 1 after treatment, mean pain assessment ranged from 4.5 to 4.9 (scale, 0 to 10) and decreased to 1.1 or less (range, 0.7 to 11) by day 5 (Fig 1) . Edema, mucosal erosion, paresthesias, referred pain, and tinnitus were infrequently noted and were usually of mild or moderate
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severity (Fig 2) . No significant changes in speech, swallowing, taste, or throat irritation were noted (Table 3) . Base of tongue RFVTR resulted in significant symptomatic improvement in multiple self-reported outcome measures. Epworth Sleepiness Scale, FOSQ, VAS of sleepiness, VAS of snoring, and SF-36 improved. (Figs  3 and 4, Tables 4 and 5) .
For the CPAP comparison group, 100 patients were enrolled and 77 patients provided follow-up data. Mean reported compliance was 5.9 ± 2.1 hours per night. Comparisons between the nasal CPAP and base of tongue groups showed no differences in baseline apnea severity or other demographic characteristics. Initial self-reported outcomes were similar with the exception of SF-36/role-physical (49.3 vs 66.3) and SF-36/vitality (32 vs 40.5) in the nasal CPAP and base of tongue groups respectively (Table 5) . For all other variables, effect sizes were comparable and significant improvements in both groups were noted in the primary measures of ESS, FOSQ, Snore 25, and SF-36 (Tables 4 and  5 , Fig 3) .
For the surgical group, the mean AHI decreased from 40.5 ± 21.5 events per hour to 32.8 ± 22.6 events per hour (P < 0.01) (Fig 5) . The apnea index (AI) decreased from 16.3 ± 19.6 to 11.7 ± 13.5 (P = 0.04) events per hour (Fig 5) . Lowest oxygen saturation changed from 80.6% ± 8.8% to 82.2% ± 7.1% (P = NS). Individual results for the 3 outcomes varied widely (Figs 5-7) . Using a priori definitions of a successful response as, a 50% reduction in AHI and an AHI < 20 events per hour, 11 (20%) responded based on AHI. Since definitions of hypopnea vary widely, apnea index (AI) was also used to identify treatment defined as a reduction of greater than 50% and an AI of less than 10 events per hour. Using this definition, 33% (17 of 51 patients with AI reported) responded. Successful responses were not related to changes in positional sleep by polysomnography. Supine AHI decreased in the successful responder group (52.8 ± 44.9 to 14.5 ± 11.2, P < 0.05). Increased time in supine sleep and the presence of positional sleep apnea (supine AHI > 2 times total AHI) may explain the worsening of AHI in 3 (25%) of 12 patients. Overall, no changes in sleep architecture were noted for the group.
Subgroup analysis demonstrated no difference in treatment effect stratified by apnea severity (mild AHI < 20, moderate AHI 20-40, and severe AHI > 40), total energy delivered (< 15,000 J or > 15,000 J) or by 
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Volume 125 Number 4 WOODSON et al 307 changes in body mass index. Body mass index for the group decreased by 0.2 kg/M 2 (95% confidence interval 0.6 to 0.2 kg/M 2 , P > 0.05). There was no relationship between changes in lowest oxygen saturation and changes in AHI after treatment (r = 0.01, P > 0.5).
There was a trend for nonresponder patients to have a higher percentage of "other" pharyngeal surgeries compared to responders (48.9% vs 18.2%, P = 0.09). A major predictor of outcomes was the amount of local anesthetic solution and electrolyte injected at the time of treatment (r = 0.43, P < 0.01, Fig 8) . The amount of solution (defined as local anesthesia and/or supplemental injected saline solution) was standardized by the creation of an arbitrary "electrolyte index" (electrolyte index = cubic centimeter of total electrolyte injected/total joules delivered. A significantly greater treatment effect was noted in patients with a high electrolyte index (upper 50th percentile) as compared to a low electrolyte index (lower 50th percentile) (Fig 9) .
Complication rates for this study were low, with an incidence of serious infections of less than 1% of treatment lesions delivered (Table 6 ). Four suppurative base of tongue infections were noted in this study; 1 required surgical incision and drainage, 1 was treated with needle aspiration, and 2 drained spontaneously. In all cases, the infection was virulent with rapid onset of sepsis, severe tongue pain, tongue edema, and neck swelling. Although no CN XII damage was observed, several 
patients did have mild and transient tongue deviations after procedures. The case of unilateral blindness occurred in a patient who experienced prior unreported transient ischemic attacks of unilateral vision loss. Full neurologic evaluation, MRI scanning, and EEG were performed with no association to RFTVR identified aside from the event occurring during the perioperative time period. All other adverse events resolved within the 6 weeks before subsequent procedures. No patient in this study required acute airway intervention.
DISCUSSION
The majority of the participants in both the nasal CPAP and the tongue reduction treatment arm reported substantial subjective improvement in their SDB-related symptoms. However, for the tongue reduction arm, subjective improvement was not reflected by similar improvement in polysomnography. This is similar to studies with other treatment approaches as well. 7 Among the possible explanations include a treatment placebo effect. Both sham nasal CPAP and placebo "sleep apnea" pill have demonstrated small but statistically significant improvements in OSAS subjective symptoms. 8, 9 The current study differs from other studies that have evaluated subjective improvement with only short-term follow-up. The current study evaluated patients over 6 to 12 months or more. Considering the relatively long duration of time needed to complete a series of treatments and follow-up, all punctuated by periodic questionnaires, ongoing signs and symptoms of snoring and sleepiness (that affect others such as bed partner, family, and co-workers) likely would have been noted and reported. Symptom improvement was main- 
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tained and similar to the CPAP comparison group over the length of this study (average time, 11 months). It is possible, although unproven, that pharyngeal surgery reduces airway resistance and the work of breathing, which may affect sleep and clinical outcomes. Other studies have demonstrated that apneas and particularly hypopneas explain very little of the variation of both objective and subjective sleepiness. 7 Patient-recorded subjective outcomes showed a relationship with severity of disease. In mild OSAS patients, base of tongue RFVTR produced significantly higher effect sizes on self-reported outcomes than nasal CPAP. Conversely, nasal CPAP demonstrated greater effect sizes on patients with moderate and severe obstructive sleep apnea syndrome.
A major finding of this study is the association of the volume of injected local anesthetic and electrolyte solution at the time of treatment with treatment outcomes. Why this would have had such a major relationship to the change in the AHI is consistent with the postulated mechanism of treatment effectiveness by reducing tongue volume. The effectiveness of other excisional tongue procedures is also influenced by the degree of volume reduction. Laser midline glossectomy has demonstrated lower success rates than either lingualplasty or hyoepiglottoplasty, which are much more aggressive tongue reduction procedures. 10 The initial resistive lesion produced by radiofrequency energy results from direct ionic agitation around the electrode and dissipates from the electrode source as a function of the radius to the fourth power. Outside of this resistive lesion, tissue is coagulated by conductive heat spread. It Individual data on change in AI is depicted before and after treatment (P < 0.04).
has been shown that injecting saline solution in the treatment area for radiofrequency can increase maximal lesion size. 11 This may be due to any or all of the following: increasing effective surface of the electrode, decreasing tissue impedance, increasing tissue contact allowing homogenous current and energy dispersion, and diffusion of the heated saline solution into the tissue.
The findings of the current study could have profound implication on maximizing tissue volume reduction for temperature-controlled radiofrequency procedures. Regardless, it is clear that technique may be critically important in the performance of radiofrequency tissue ablation for the treatment of OSAS. Although suboptimal electrolyte injection may explain some of the treatment failures by polysomnography, there are other possible confounding factors. Study participants in the tongue reduction treatment arm represented failures of other procedures, including those undertaken to control a retroglossal obstructive level. Multiple causes contribute to UPPP and other surgical failures in obstructive sleep apnea. 12 In fact, the assumption that prior performance of a palatopharyngoplasty necessarily results in adequately treated retropalatal obstruction is not supported by data. 13 This could be a likely factor in this study population. Therefore, for these individuals one would expect base of tongue RFVTR to at best be only partially successful. Why surgical failures occur despite a seemingly well planned out and site selected approach to identified obstructive levels is not understood. Reasons not addressed by specific site directed airway surgery may be the initial and ongoing factors that makes one a nonresponder. Better and more universally accepted methods of selection as to which patient benefits most from which type of treatment are needed. Until this is established, this study demonstrates that RFVTR tongue reduction, with its mini- Treatment effectiveness differed in subjects with a high electrolyte index (electrolyte index in the top 50th percentile) compared with subjects with low electrolyte indexes (P < 0.002).
mally invasive low morbidity, can improve a significant enough proportion of previous treatment failures to warrant its consideration as a treatment option in previous surgical nonresponders. Although no patients in this study required airway intervention, airway compromise can potentially occur, and this warrants a conservative treatment approach with careful observation, especially in patients with more severe respiratory disturbance.
CONCLUSION
This study demonstrates that temperature-controlled RFVTR tongue reduction diminishes the severity of OSAS. It is relatively well tolerated and of low morbidity. Subjective outcomes were comparable between the TCRF and CPAP treatment groups. In mild OSA, where symptomatic improvement contributes more to an acceptable treatment outcome, this procedure could be an alternative to CPAP in patients that have failed previous surgical treatments. Modifying the present procedure by increasing electrolyte solution injection could significantly improve treatment effect. Further randomized clinical trials are needed to address this issue.
